Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1724 | 0.6887 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1724 | 0.6887 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.1724 | 0.6887 | 0.9706 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1724 | 0.6887 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1035 | 0.2023 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1035 | 0.2023 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Giardia lamblia | Hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1724 | 0.6887 | 0.9706 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1754 | 0.7096 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Onchocerca volvulus | 0.1754 | 0.7096 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.